Humira Biosimilar Industry Forecast to Hit $5.82 Billion by 2029 With a Strong 12.3% CAGR

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Growth Projections For The Humira Biosimilar Market Size During 2025–2029?

The humira biosimilar market size has shown rapid expansion over recent years. It is projected to increase from $3.28 billion in 2024 to $3.67 billion in 2025, achieving a compound annual growth rate (CAGR) of 12.0%. This historical growth can be linked to a heightened demand for affordable options, increased regulatory body approvals for biosimilars, a growing incidence of autoimmune conditions, wider access to healthcare in new markets, and the substantial cost of original biologic drugs.

The humira biosimilar market size is projected to experience substantial expansion in the coming years. Its valuation is anticipated to reach $5.82 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 12.3%. This expansion during the projection period is driven by improvements in biosimilar development technologies, a heightened focus on managing healthcare costs, the increasing expiry of patents for original biologic drugs, better market access and reimbursement frameworks, and the growing uptake of biosimilars for treating oncology and autoimmune conditions. Key trends expected during this period involve a rise in the approval of additional biosimilars, continuous progress in manufacturing methods, intensified research and development efforts, the creation and subsequent approval of new biosimilar medicines, and ongoing innovations in drug formulation.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24244&type=smp

Which Industry Drivers Are Expected To Accelerate The Humira Biosimilar Market From 2025 To 2029?

The escalating occurrence of autoimmune diseases is projected to boost the growth of the humira biosimilar market in the coming period. Autoimmune conditions arise when the body’s immune system mistakenly targets and assaults its own healthy cells, tissues, or organs. The rising frequency of these diseases is linked to environmental pollution, which disrupts the immune system and elevates the risk of autoimmune reactions. Humira biosimilars operate by obstructing tumor necrosis factor (TNF), a protein responsible for causing inflammation in autoimmune ailments. This mechanism helps to diminish the immune response, thereby alleviating symptoms and preventing harm to healthy tissues. For instance, in June 2024, the Australian Institute of Health and Welfare, an Australia-based government organization, reported that an estimated 514,000 people (2.0%) in Australia were affected by rheumatoid arthritis in 2022, impacting 2.5% of females and 1.6% of males. Consequently, the increasing incidence of autoimmune disorders is propelling the expansion of the humira biosimilar market.

Which Key Segments Fueling The Humira Biosimilar Market?

The humira biosimilarmarket covered in this report is segmented –

1) By Product Type: Adalimumab Biosimilars; Other Types

2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels

3) By Application: Rheumatoid Arthritis; Psoriasis; Crohn’s Disease; Ulcerative Colitis; Ankylosing Spondylitis; Other Applications

Subsegments:

1) By Adalimumab Biosimilars: Fully Human Monoclonal Antibodies; Fragment Crystallizable (Fc) Region Modified Biosimilars; High-Concentration Formulations; Citrate-Free Formulations

2) By Other Types: Biosimilars Of Other Tumor Necrosis Factor (TNF) Inhibitors; Interchangeable Biosimilars; Pegylated Biosimilars; Non-Adalimumab Monoclonal Antibody Biosimilars

Which Market Trends Are Creating New Opportunities In The Humira Biosimilar Industry?

Companies operating in the humira biosimilar market are primarily focused on creating advanced products, such as tumor necrosis factor (TNF) blockers, to present more affordable solutions for managing autoimmune diseases. Tumor necrosis factor (TNF) blockers are biologic medications that work by suppressing the activity of TNF, a vital protein contributing to inflammation. For example, in July 2023, Organon & Co., a US-based pharmaceutical company, collaborated with Samsung Bioepis Co., Ltd., a South Korea-based biotech company, to launch HADLIMA, a biosimilar to Humira. HADLIMA is supplied in both citrate-free high-concentration (100 mg/mL) and citrate-containing low-concentration (50 mg/mL) formats, matching the options of the originator Humira, aiming to improve patient access and affordability. The product is provided at a considerable discount, approximately 85% lower than Humira’s list price, and includes patient support programs. This launch occurred after a global settlement that permitted U.S. supply, marking a significant step in expanding treatment choices for chronic autoimmune diseases in the U.S.

Which Major Industry Participants Are Leading The Humira Biosimilar Market Growth?

Major companies operating in the humira biosimilar market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., LG Chem Ltd., Amgen Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Mylan N.V., Sandoz Group AG, Fresenius Kabi AG, Celltrion Inc., Biocon Limited, Torrent Pharmaceuticals, Samsung Bioepis Co. Ltd., Alvotech, Coherus BioSciences Inc., Zydus Cadila, Hetero Drugs Ltd., Fujifilm Kyowa Kirin Biologics, Synermore Biologics, CVS Health.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/humira-biosimilar-global-market-report

How Is Humira Biosimilar Market Demand Varying Across Different Regions?

North America was the largest region in the humira biosimilar market in 2024. The regions covered in the humira biosimilar market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Humira Biosimilar Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24244&type=smp

Browse Through More Reports Similar to the Global Humira Biosimilar Market 2025, By The Business Research Company

Autoimmune Disease Diagnosis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report

Granulocyte Colony Stimulating Factors Market 2025

https://www.thebusinessresearchcompany.com/report/granulocyte-colony-stimulating-factors-market

Drug Delivery Devices Market 2025

https://www.thebusinessresearchcompany.com/report/drug-delivery-devices-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795